Treatment Segment Analysis: Biologics (Largest Segment) vs Systemic (Fastest-Growing Segment)

The biologics segment dominated the psoriasis drugs market with a 49.16% share in 2026, reflecting the growing role of targeted therapies in managing moderate-to-severe psoriasis and addressing underlying inflammatory pathways. Biologic treatments offer more specific mechanisms of action than many conventional therapies, supporting their use when disease severity or treatment response requires advanced therapeutic approaches. Increasing emphasis on effective disease control and personalized treatment strategies is strengthening demand for therapies capable of targeting specific immune mechanisms. Continued development of targeted treatment approaches and greater clinical familiarity with biologic therapies are reinforcing their established market position.

Systemic treatments are expanding at the fastest pace as the need for therapies capable of addressing psoriasis beyond localized skin symptoms continues to grow. Systemic approaches can be particularly relevant for patients with more extensive or persistent disease, creating demand for treatment options that work throughout the body. Advances in therapeutic development and increasing attention to individualized treatment selection are supporting greater use of systemic approaches. The segment is also benefiting from continued efforts to improve treatment effectiveness, tolerability, and convenience, encouraging broader consideration of systemic therapies within psoriasis management.

Route of Administration Segment Analysis: Parenteral (Largest Segment) vs Topical (Fastest-Growing Segment)

Parenteral administration represented the largest route of administration in the psoriasis drugs market, accounting for 44.07% in 2026, supported by the importance of injectable delivery for advanced psoriasis therapies, particularly treatments requiring systemic exposure. Parenteral administration can provide controlled delivery of therapies that target immune and inflammatory mechanisms, making it an important route for patients requiring more advanced disease management. Its established association with biologic therapies and the growing use of targeted treatment approaches continue to support demand. Clinical familiarity and the therapeutic requirements of moderate-to-severe psoriasis further reinforce the role of parenteral delivery.

The topical route is growing at the fastest rate as patients and healthcare providers continue to value localized treatment options that can be applied directly to affected skin. Topical therapies offer a convenient approach for managing localized symptoms and can be incorporated into treatment regimens without requiring systemic administration. Ongoing development of improved topical formulations is broadening their usability and supporting patient preference for accessible treatment options. Greater emphasis on individualized care, ease of application, and targeted management of skin manifestations is contributing to increasing adoption of topical psoriasis therapies.